Siegel RL, et al. Cancer Statistics, 2021. CA: a Cancer J Clin. 2021;71(1):7-33.

Google Scholar 

Reck M, et al. Management of non-small-cell lung cancer: recent developments. Lancet (London, England). 2013;382(9893):709–19.

Article  CAS  PubMed  Google Scholar 

Park K, et al. Pan-Asian adapted ESMO clinical practice guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS SSO and TOS. Ann Oncol. 2020;31(2):191–201.

Article  CAS  PubMed  Google Scholar 

Rittmeyer A, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. The Lancet. 2017;389(10066):255–65.

Article  Google Scholar 

Suresh K, et al. Immune checkpoint immunotherapy for non-small cell lung cancer: benefits and pulmonary toxicities. Chest. 2018;154(6):1416–23.

Article  PubMed  PubMed Central  Google Scholar 

Yi M, et al. Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors. Mol Cancer. 2018;17(1):129.

Article  PubMed  PubMed Central  Google Scholar 

Ettinger DS, et al. NCCN guidelines insights: non-small cell lung cancer. J Natl Compr Cancer Netw: JNCCN. 2021;19(3):254–66.

Article  CAS  PubMed  Google Scholar 

Sunshine J, Taube JM. PD-1/PD-L1 inhibitors. Curr Opin Pharmacol. 2015;23:32–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gerlinger M, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366(10):883–92.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cavalli FMG, et al. Intertumoral heterogeneity within medulloblastoma subgroups. Cancer Cell. 2017;31(6):737-754.e6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jia Q, et al. Tracking neoantigens by personalized circulating tumor DNA sequencing during checkpoint blockade immunotherapy in non-small cell lung cancer. Adv Sci (Weinh). 2020;7(9):1903410.

Article  CAS  PubMed  Google Scholar 

Kantarjian H, Yu PP. Artificial intelligence, big data, and cancer. JAMA Oncol. 2015;1(5):573–4.

Article  PubMed  Google Scholar 

Chen CL, et al. Deep learning in label-free cell classification. Sci Rep. 2016;6(1):21471.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yan X, Ding J, Cheng HD. A Novel Adaptive Fuzzy Deep Learning Approach for Histopathologic Cancer Detection. Annu Int Conf IEEE Eng Med Biol Soc. 2021 Nov;2021:3518–3521.

Serag A, et al. Translational AI and deep learning in diagnostic pathology. Front Med. 2019;6:185.

Article  Google Scholar 

Dong Y, et al. Multi-channel multi-task deep learning for predicting EGFR and KRAS mutations of non-small cell lung cancer on CT images. Quant Imaging Med Surg. 2021;11(6):2354–75.

Article  PubMed  PubMed Central  Google Scholar 

Davoli T, et al. Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. Science. 2017;355(6322):eaaf8399.

Article  PubMed  PubMed Central  Google Scholar 

Carbone DP, et al. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N Engl J Med. 2017;376(25):2415–26.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hellmann MD, et al. Nivolumab plus Ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med. 2018;378(22):2093–104.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Peters S, et al. Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial. Nat Med. 2022;28(9):1831–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Singal G, et al. Association of patient characteristics and tumor genomics with clinical outcomes among patients with non-small cell lung cancer using a clinicogenomic database. JAMA. 2019;321(14):1391–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stover DG, et al. Association of cell-free DNA tumor fraction and somatic copy number alterations with survival in metastatic triple-negative breast cancer. J Clin Oncol. 2018;36(6):543–53.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bernard V, et al. Circulating nucleic acids are associated with outcomes of patients with pancreatic cancer. Gastroenterology. 2019;156(1):108-118.e4.

Article  CAS  PubMed  Google Scholar 

Bratman SV, et al. Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. Nature Cancer. 2020;1(9):873–81.

Article  CAS  PubMed  Google Scholar 

Ricciuti B, et al. Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC). J Immunother Cancer. 2021;9(3): e001504.

Article  PubMed  PubMed Central  Google Scholar 

Vokes NI, et al. Circulating tumor DNA (ctDNA) dynamics and survival outcomes in patients (pts) with advanced non-small cell lung cancer (aNSCLC) and high (>50%) programmed cell death-ligand 1 (PD-L1) expression, randomized to cemiplimab (cemi) vs chemotherapy (chemo). J Clin Oncol. 2023;41(16_suppl):9022–9022.

Article  Google Scholar 

Guibert N, et al. Monitoring of KRAS -mutated ctDNA to discriminate pseudo-progression from true progression during anti-PD-1 treatment of lung adenocarcinoma. Oncotarget. 2017;8(23):38056.

Article  PubMed  PubMed Central  Google Scholar 

Lee CK, et al. Checkpoint inhibitors in metastatic EGFR-mutated non–small cell lung cancer—a meta-analysis. J Thorac Oncol. 2017;12(2):403–7.

Article  PubMed  Google Scholar 

Lee CK, et al. Clinical and molecular characteristics associated with survival among patients treated with checkpoint inhibitors for advanced non-small cell lung carcinoma: a systematic review and meta-analysis. JAMA Oncol. 2018;4(2):210–6.

Article  PubMed  Google Scholar 

Rizvi NA, et al. Nivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol. 2016;34(25):2969–79.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lu S, et al. VP9-2021: ORIENT-31: Phase III study of sintilimab with or without IBI305 plus chemotherapy in patients with EGFR mutated nonsquamous NSCLC who progressed after EGFR-TKI therapy. Ann Oncol. 2022;33(1):112–3.

Article  Google Scholar 

Socinski MA, et al. IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous NSCLC. J Thorac Oncol. 2021;16(11):1909–24.

Article  CAS  PubMed  Google Scholar 

Park S, et al. Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR- or ALK-Mutated Non-Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04). J Clin Oncol. 2023 Oct 20:JCO2301891.

Mok T, et al. Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722. J Clin Oncol. 2024 Jan 22:JCO2301017.

Yang JC-H, et al. Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study. J Clin Oncol. 2023;41(17_suppl):9000.

Article  Google Scholar 

Negrao MV, et al. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer. J immunother cancer. 2021;9(8):e002891.

Article  PubMed  PubMed Central  Google Scholar 

Garassino MC, et al. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. Lancet Oncol. 2018;19(4):521–36.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mazieres J, et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol. 2019;30(8):1321–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Offin M, et al. Immunophenotype and response to immunotherapy of RET-rearranged lung cancers. JCO Precis Oncol. 2019;3:1–8.

Article  Google Scholar 

Lee J, et al. Characteristics and outcomes of RET-rearranged Korean non-small cell lung cancer patients in real-world practice. Jpn J Clin Oncol. 2020;50(5):594–601.

Article  PubMed  Google Scholar 

Chang G-C, et al. ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients. Sci Rep. 2020;10(1):21063.

Article  CAS